Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 501,432
  • Shares Outstanding, K 122,003
  • Annual Sales, $ 57,560 K
  • Annual Income, $ -44,140 K
  • EBIT $ -56 M
  • EBITDA $ -44 M
  • 60-Month Beta 1.65
  • Price/Sales 9.43
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 75.30% (-3.80%)
  • Historical Volatility 111.62%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 474.07% on 03/10/25
  • IV Low 75.30% on 02/27/26
  • Expected Move (DTE 21) 0.55 (13.92%)
  • Put/Call Vol Ratio 4.72
  • Today's Volume 3,563
  • Volume Avg (30-Day) 5,718
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 54,784
  • Open Int (30-Day) 139,951
  • Expected Range 3.42 to 4.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.15
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +34.81%
on 01/30/26
4.39 -10.02%
on 02/02/26
+0.48 (+13.83%)
since 01/27/26
3-Month
2.93 +34.81%
on 01/30/26
6.74 -41.35%
on 12/08/25
-2.27 (-36.50%)
since 11/26/25
52-Week
2.12 +86.32%
on 05/13/25
7.55 -47.68%
on 10/20/25
+1.23 (+45.22%)
since 02/27/25

Most Recent Stories

More News
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 3.97 (-3.41%)
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 3.97 (-3.41%)
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 3.97 (-3.41%)
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) --...

AQST : 3.97 (-3.41%)
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J.,...

AQST : 3.97 (-3.41%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss...

AQST : 3.97 (-3.41%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors...

AQST : 3.97 (-3.41%)
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss...

AQST : 3.97 (-3.41%)
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”)...

AQST : 3.97 (-3.41%)
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Deficiencies limited to packaging and administration Company believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026 Remains well-capitalized and anticipates ending...

AQST : 3.97 (-3.41%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 4.43
2nd Resistance Point 4.33
1st Resistance Point 4.22
Last Price 3.97
1st Support Level 4.01
2nd Support Level 3.90
3rd Support Level 3.79

See More

52-Week High 7.55
Fibonacci 61.8% 5.48
Fibonacci 50% 4.84
Fibonacci 38.2% 4.19
Last Price 3.97
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar